Contribution of the androgen receptor to prostate cancer predisposition and progression

Cancer and Metastasis Reviews

Volumn 20, Issue 3-4, 2001, Pages 207-223

  Buchanan, Grant ^a   Irvine, Ryan A ^b   Coetzee, Gerhard A ^b   Tilley, Wayne D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgen ablation therapy; Androgen signaling axis; CAG; GGC; Mutation

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALLELE; APOPTOSIS; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; GENE TARGETING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA TRANSLATION; TRANSACTIVATION;

EID: 0035740251     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015531326689     Document Type: Review

References (143)

1. Regulation of androgen action
2. Molecular action of androgen in the normal and neoplastic prostate
3. Characterization and expression of a cDNA encoding the human androgen receptor
4. The steroid receptor superfamily: More excitement predicted for the future
5. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
6. Clinical review 37: Endocrine treatment of prostate cancer
7. Estrogen receptor cofactors expression in breast and endometrial human cancer cells
8. Advanced prostatic carcinoma: Early v's late endocrine therapy
9. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
10. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function
11. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
12. Androgen receptors in prostate cancer
13. Prostate cancer: Molecular biology of early progression to androgen independence
14. The role of the androgen receptor in the development and progression of prostate cancer
15. Genetic regulation of androgen action
16. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups
17. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
18. Sequence variation and size ranges of CAG repeats in the Machado-Joseph disease, spinocerebellar ataxia type 1 and androgen receptor genes
19. Evolution of the primate androgen receptor: A structural basis for disease
20. Haplotype analysis of the delta 2642 and (CAG)n polymorphisms in the Huntington's disease (HD) gene provides an explanation for an apparent 'founder' HD haplotype
21. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
22. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy
23. A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure
24. Familial bulbospinal muscular atrophy associated with testicular atrophy and sensory neuropathy (Kennedy-Alter-Sung syndrome). Autopsy case report of two brothers
25. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy
26. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
27. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies
28. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility
29. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
30. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and nonprostate cell lines
31. Steroid receptor interactions with heat shock protein and immunophilin chaperones
32. Steroid receptor induction of gene transcription: A two-step model
33. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells
34. Multiple parameters control the selectivity of nuclear receptors for their response elements. Selectivity and promiscuity in response element recognition by retinoic acid receptors and retinoid X receptors
35. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains
36. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses
37. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
38. Structural determinants of nuclear receptor assembly on DNA direct repeats
39. Nuclear receptors. How to finger DNA
40. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions
41. Re: Prostate cancer and the androgen receptor
42. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
43. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
44. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer
45. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
46. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
47. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China
48. The impact of differential binding of wild-type RARalpha, PML-
49. Links between genetic and environmental factors and prostate cancer risk
50. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
51. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
52. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
53. The polymorphic exon I androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer
54. Significance of the cag repeat polymorphism of the androgen receptor gene in prostate cancer progression
55. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways
56. Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk
57. Polymorphic repeats in the androgen receptor gene in high-risk sibships
58. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men
59. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy
60. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator
61. The small nuclear GTPase Ran: How much does it run?
62. Studying human mutations by sperm typing: Instability of CAG trinucleotide repeats in the human androgen receptor gene
63. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells
64. The androgen receptor gene GGN microsatellite and prostate cancer risk
65. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis
66. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy
67. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy
68. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma
69. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis
70. Immunocytochemical assay for androgen receptors in prostate cancer: A prospective study of 63 cases with long-term follow-up
71. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer
72. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
73. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer
74. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
75. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells
76. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer
77. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells
78. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
79. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
80. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript
81. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes
82. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
83. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma
84. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines
85. Collocation of androgen receptor gene mutations in prostate cancer
86. Androgen receptor signaling in androgen-refractory prostate cancer
87. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains
88. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma
89. Androgen receptor gene expression in human prostate carcinoma cell lines
90. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
91. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer
92. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
93. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
94. Androgen receptor structure and function in prostate cancer
95. Androgen receptor mutations in prostate cancer
96. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer
97. A canonical structure for the ligand-binding domain of nuclear receptors
98. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
99. Structural evidence for ligand specificity in the binding domain of the human Androgen receptor: Implications for pathogenic gene mutations
100. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
101. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
102. Androgen receptor mutations in prostate cancer
103. Transcription activating and repressing functions of the androgen receptor are differentially influenced by mutations in the deoxyribonucleic acid-binding domain
104. Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding
105. Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer
106. Quantitative differences in androgen and glucocorticoid receptor DNA binding properties contribute to receptor-selective transcriptional regulation
107. Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor
108. The histone acetylase PCAF is a nuclear receptor coactivator
109. A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins
110. Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription
111. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor
112. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain
113. Transcriptional activation and transient expression of the human androgen receptor
114. Microsatellite mutation (CAG24->18) in the androgen receptor gene in human prostate cancer
115. Genetic alterations of androgen receptor gene in Japanese human prostate cancer
116. Androgen receptor gene mutations in hormone-refractory prostate cancer
117. Disruption of the polyglutamine tract results in increased ligand-induced transcriptional activity of the androgen receptor
118. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins
119. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1
120. Receptor accessory factor enhances specific DNA binding of androgen and glucocorticoid receptors
121. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
122. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer
123. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway
124. Her-2-neu expression and progression toward androgen independence in human prostate cancer
125. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
126. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
127. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells
128. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
129. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-Year clinical experience
130. Maximal androgen blockade for advanced prostate cancer
131. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance
132. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
133. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
134. Antiandrogen withdrawal syndrome with nilutamide
135. Withdrawal phenomenon with the antiandrogen casodex
136. Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
137. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol
138. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome
139. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate
140. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
141. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
142. Selection of androgen receptor mutations in prostate cancers treated with androgen antagonists
143. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells